New Vice President at Vitrolife

 | Source: Vitrolife AB Vitrolife AB 

Maria Forss has today been appointed Vice President, responsible for Business
Development and Global Marketing. Maria Forss joins Vitrolife from P.U.L.S,
where she is responsible for Business Development.
Maria has previously worked as the CEO of DuoCort Pharma, and at AstraZeneca in
different positions within Marketing and Product Management. Maria takes up her
post on October 1.

The role of Vice President is new and will strengthen Vitrolife’s management
function.

“With her solid experience of business development and marketing, Maria will be
an excellent asset for us in the work of further strengthening Vitrolife’s
competitiveness. We warmly welcome Maria to the assignment of Vice President and
I am pleased to gain yet another competent co-worker at Vitrolife,” says
Vitrolife’s CEO Thomas Axelsson.

July 10, 2012

Gothenburg, Sweden

VITROLIFE AB (publ)

Thomas Axelsson

CEO
Queries should be addressed to:

Thomas Axelsson, CEO, phone 46 31 721 80 01

Mikael Engblom, CFO, phone 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on July
10, 2012 at 3:00 p.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
Vitrolife (http://www.vitrolife.com/en/Corporate/) is a global
biotechnology/medical device Group that works in the areas of Fertility and
Transplantation. The Fertility (http://www.vitrolife.com/en/Fertility/) product
area works with nutrient solutions (media), cryopreservation products and
advanced consumable instruments such as needles and pipettes, for the treatment
of human infertility. Work is also carried out to enable the use and handling of
stem cells for therapeutic purposes. The
Transplantation (http://www.xvivoperfusion.com/transplantation/) product area
works with solutions and systems for assessing and preserving organs outside the
body, so as to be able to select usable organs and keep them in optimal
condition pending transplantation.

Vitrolife (http://www.vitrolife.com/en/Corporate/) today has approximately 220
employees and its products are sold in almost 90 markets. The company is
headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife
share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is listed on
NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Small Cap.

________________________________________________________________________________
_ 
________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/

Attachments